Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 2 Interventional Results available

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186
View directory record Official record
Conditions
Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

NCT00000854
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Nandrolone decanoate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 2 Interventional

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

NCT02815332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
9 Years to 40 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Coral Gables, Florida • Lake Mary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

NCT04163263
View directory record Official record
Conditions
Moderate to Severe Acne Vulgaris
Interventions
BOS-356, Vehicle
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Fremont, California • Sanford, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

NCT03338816
View directory record Official record
Conditions
Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions
Givosiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

NCT03717506
View directory record Official record
Conditions
Acne Vulgaris
Interventions
GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 23, 2026, 7:04 PM EDT
Recruiting Phase 2 Interventional

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

NCT07133633
View directory record Official record
Conditions
Radiographic Axial Spondyloarthritis
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 23, 2026, 7:04 PM EDT
Terminated Not applicable Interventional

Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment

NCT02211560
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Phosphatidylserine, Placebo
Other
Lead sponsor
Enzymotec
Industry
Eligibility
65 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 4 Interventional Results available

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

NCT00257920
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
Interventions
Zemplar® injection, Hectorol® injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Bellevue, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

NCT03770780
View directory record Official record
Conditions
Healthy Volunteer
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

NCT03500679
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wichita, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 23, 2026, 7:04 PM EDT
Withdrawn Phase 2 Interventional

Erlotinib for Treatment of Psoriasis

NCT01006096
View directory record Official record
Conditions
Psoriasis
Interventions
erlotinib, placebo tablet
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

NCT00999141
View directory record Official record
Conditions
Face-lift, Facial Rhytidectomy
Interventions
FS VH S/D 4 s-apr
Biological
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Beverly Hills, California • Atlanta, Georgia • Evans, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

NCT01926782
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Statin
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 23, 2026, 7:04 PM EDT
Active, not recruiting Phase 2 Interventional

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

NCT05979779
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
Interventions
HU6, Placebo
Drug · Other
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Chula Vista, California • Los Angeles, California • Montclair, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 4 Interventional Results available

Study Using Pregnenolone to Treat Bipolar Depression

NCT01409096
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 23, 2026, 7:04 PM EDT
Completed Phase 3 Interventional

Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee

NCT00365586
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ketoprofen Topical Patch , 20%
Drug
Lead sponsor
Alkemira SA
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 7:04 PM EDT
Withdrawn Phase 2 Interventional

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

NCT00528827
View directory record Official record
Conditions
Hypertension
Interventions
Cardene® I.V.
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 23, 2026, 7:04 PM EDT